Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2019 | A promising future for gemcitabine-oxaliplatin in cisplatin-unfit advanced urothelial carcinoma

Jae-Lyun Lee • 15 Mar 2019
GU Cancers 2019
Bladder Cancer Genitourinary Cancer Gemcitabine Oxaliplatin
COACH

Jae-Lyun Lee, MD, of the Asan Medical Center, Seoul, South Korea, speaks about the promising results of gemcitabine-oxaliplatin (GemOx) for advanced urothelial carcinoma (UC) to date, and discusses future directions for the treatment of cisplatin-unfit advanced UC. This video was filmed at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA.

More from Jae-Lyun Lee

COACH trial update: GemOx vs. GCb in cisplatin-unfit advanced urothelial carcinoma
4:21
COACH trial update: GemOx vs. GCb in cisplatin-unfit advanced urothelial carcinoma
Jae-Lyun Lee • 15 Mar 2019

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026
The content of VJOncology is intended for healthcare professionals